Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer, is scheduled to present to the investment community at the UBS 2006 Global Specialty Pharmaceuticals Conference. The presentation will include an update on the company’s mid-stage pipeline, including Liarozole and Rambazole.
